Copyright © Inderes 2011 - present. All rights reserved.

Remedy Entertainment

15.60 EUR

-1.76 %

11,409 following

REMEDY

NASDAQ Helsinki

Software

Technology

-1.76 %
+18.00 %
+11.11 %
-10.14 %
+10.95 %
+14.20 %
-31.13 %
-59.16 %
+133.18 %

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more
Market cap
212.79M EUR
Turnover
105.54K EUR
P/E (adj.) (25e)
-15.82
EV/EBIT (adj.) (25e)
-12.71
P/B (25e)
3.86
EV/S (25e)
3.36
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
19.00 EUR
Updated
2025-12-16
Disclaimer
Atte Riikola
Atte Riikola

Analyst

Latest research

Latest analysis report

Released: 2025-12-17

Latest extensive report

Released: 2024-12-18

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10/2
2026

Annual report '25

5/5
2026

Business review Q1'26

11/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
You sure are a precise guy, Akee! And I’ve been tangled up with my own Excels over the weekend. My calculations for Annapurna’s share are correct for 2026. Marketing costs of about 8 MEUR have also been deducted there, in addition to distribution costs, when calculating Annapurna...
yesterday
by Atte Riikola
36
It’s really good that you spotted that. I shouldn’t fool around with assumptions myself. Remedy’s forecast model is probably the most complex of my cases, as forecasting isn’t always straightforward. I might as well go through the other assumptions now, an update will follow
yesterday
by Atte Riikola
29
Sorry @Atte_Riikola, I didn’t mean to open a can of worms and cause extra work. I genuinely believe that you have done a commendable job with your analysis, for example, with a good scenario-based approach. Over time, I have learned a lot from your analyses and developed as an investor...
yesterday
by Pölhölän Akee
28
Thanks again for the good analysis @Atte_Riikola I read through the analysis last night. It may be, or is even likely, that I am an idiot or have made some simple mistake (or both), but because of this, or despite it, I can’t quite make sense of Resonant’s sales calculations. In ...
yesterday
by Pölhölän Akee
26
Here are the updated forecasts. While working on Excel, I noticed that the depreciations for the Control rights on the balance sheet were still assumed with the previous 2027 release schedule, so I had to fine-tune the forecasts for these as well. These relate to when Remedy bought...
8 hours ago
by Atte Riikola
24
In other news, Resonant’s wishlist estimate updated to Gamalytic Half a million wishlists surpassed on Steam. Plus consoles on top of that. Currently ranks 84th in Steam wishlists (SteamDB). Roughly a million would put it in the TOP 20 and 1.3-1.5M in the TOP 10. I stick to my previous...
8 hours ago
by Pölhölän Akee
22
In Remedy’s case, EBIT and EPS figures are quite unhelpful in the coming years, as amortizations of capitalized development costs weigh them down. Amortizations are made very front-loaded in relation to the sales of their own game releases, so a large part has already been amortized...
22 hours ago
by Atte Riikola
21
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.